Tvardi grants retention stock options to CEO, CMO, CFO; adopts severance plan

Tvardi Therapeutics, Inc.

Board approved one-time retention options: CEO Imran Alibhai 47,500, CMO John Kauh 17,500, CFO Dan Conn 17,500 shares.
Options vest 25% on Dec 16, 2026, then 36 equal monthly installments.
New Severance Plan provides cash severance, COBRA, and equity acceleration on qualifying termination with or without Change in Control.
CEO Alibhai eligible for 18 months salary plus 150% target bonus within Change in Control period; others 12 months salary plus 100% bonus.
Plan supersedes prior severance agreements; participation requires signed release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.